// App-Quantinova.ai

3030 : Different pharmacodynamic profiles of ERK1/2 inhibition can elicit comparable anti-tumor activity

Researchers

Presenter

  • Christopher Hindley

Principal Investigators

  • Luke Bevan

  • Hannah Braithwaite

  • Aurlie Courtin

  • Lynsey Fazal

  • Roberta Ferraldeschi

  • Vanessa Martins

  • Sandra Muench

  • Nicola Wallis

  • Nicola Wilsher

  • John Lyons

  • Joanne Munck

Medical Centers

  • Astex Pharmaceutical, Inc., Cambridge, United Kingdom.

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Mitogen-activated protein kinase

  • Mitogen-activated protein kinase 3

  • Phosphorylated-extracellular signal regulated kinase

  • Extracellular signal-regulated kinase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved